


TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 20050-00004 U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <div style="font-size: 2em; font-weight: bold; text-align: center;">10/520388</div>
INTERNATIONAL APPLICATION NO. PCT/KR2003/001310	INTERNATIONAL FILING DATE July 2, 2003	PRIORITY DATE CLAIMED July 3, 2002
TITLE OF INVENTION METHOD FOR PREPARING FUSION POLYPEPTIDE COMPRISING EPIDERMAL GROWTH FACTOR AND HUMAN SERUM ALBUMIN IN PLANTS		
APPLICANT(S) FOR DO/EO/US LEE, Sun; YOO, Jae-Geun; and PARK, Sun-Hee		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
Items 11 to 20 below concern document(s) or information included:		
<ol style="list-style-type: none"> 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input type="checkbox"/> A preliminary amendment. 14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A power of attorney and/or change of address letter. 17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. 18. <input checked="" type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: PCT International Preliminary Examination Report 		

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known) 10/020388 (37 CFR 1.5)		INTERNATIONAL APPLICATION NO. PCT/KR2003/001310		ATTORNEY'S DOCKET NUMBER 20050-00004											
21. The following fees are submitted: <input checked="" type="checkbox"/> a) Basic national fee..... \$300.00 <input checked="" type="checkbox"/> b) Examination fee..... \$200.00 <input checked="" type="checkbox"/> c) Search fee..... \$500.00 TOTAL OF ABOVE CALCULATIONS = \$1000.00				<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:50%;">Applicant use</th> <th style="width:50%;">Office use only</th> </tr> <tr> <td>\$ 300.00</td> <td></td> </tr> <tr> <td>\$ 200.00</td> <td></td> </tr> <tr> <td>\$ 500.00</td> <td></td> </tr> <tr> <td>\$ 1000.00</td> <td></td> </tr> </table>		Applicant use	Office use only	\$ 300.00		\$ 200.00		\$ 500.00		\$ 1000.00	
Applicant use	Office use only														
\$ 300.00															
\$ 200.00															
\$ 500.00															
\$ 1000.00															
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.															
Total Sheets	Extra sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE												
36 - 100 =	0 /50 =	0	x \$250.00												
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 0											
CLAIMS		NUMBER FILED	NUMBER EXTRA	RATE	\$										
Total claims		8 - 20 =	0	x \$50.00	\$ 0										
Independent claims		2 - 3 =	0	x \$200.00	\$ 0										
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$360.00	\$ 0										
TOTAL OF ABOVE CALCULATIONS =				\$ 1000.00											
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$ 500											
SUBTOTAL =				\$ 500.00											
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$ 0											
TOTAL NATIONAL FEE =				\$ 500.00											
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$ 0											
TOTAL FEES ENCLOSED =				\$ 500.00											
Amount to be refunded:				\$											
Amount to be charged				\$											
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>502486</u> . A duplicate copy of this sheet is enclosed. d. <input checked="" type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.															
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.															
SEND ALL CORRESPONDENCE TO: JHK Law P.O. Box 1078 La Canada, CA 91012-1078															
 SIGNATURE				Joseph Hyosuk Kim, Reg. No. 41,425 NAME 41,425 REGISTRATION NUMBER											

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Sun LEE et al.) Group Art Unit: N/A
Application Serial No.: N/A (PCT/KR2003/001310)) Examiner: N/A
Filed: Herewith)
For: **METHOD FOR PREPARING FUSION**)
POLYPEPTIDE COMPRISING EPIDERMAL)
GROWTH FACTOR AND HUMAN SERUM)
ALBUMIN IN PLANTS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUBMISSION OF SEQUENCE LISTING

Sir:


Enclosed herewith in full compliance with 37 C.F.R. §§ 1.821-1.825 is a Sequence Listing to be inserted into the specification. The Sequence Listing in no way introduces new matter into the specification.

Also submitted herewith in full compliance with 37 C.F.R. §§ 1.821-1.825 is a computer readable disk copy of the Sequence Listing. Applicant's undersigned representative hereby states that the information recorded in computer readable form is identical to the written sequence listing.

CERTIFICATE OF MAILING
(37 C.F.R. § 1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as Express Mail in an envelope addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

January 3, 2005
Date of Deposit

Harry Lee
Name of Person Mailing Paper

Signature of Person Mailing Paper

Express Mail Label No.: ER 501853882 US
PCT/KR2003/001310

10/520388
0115 Rec'd PCT/PTO 03 JAN 2005
Patent
20050-00004

Respectfully submitted,

JHK Law

Dated: January 3, 2005

By:



Joseph Hyosuk Kim, Ph.D.

Registration No. 41,425

P.O. Box 1078
La Canada, CA 91012-1078
Telephone: (818) 249-8177
Facsimile: (818) 249-8277

Enclosures: Paper and disk copy of the Sequence Listing

PAGE: 1
11/03/2005

VERIFICATION SUMMARY REPORT
PATENT APPLICATION

DATE:
TIME:

18:02:22

INPUT SEQ: C:\Documents and Settings\Joseph
Kim\My Documents\JHK Law Documents\Patent Applications\20050 - SeShin
\20050-00004\20050-00004.ST25.txt

GENERAL INFORMATION SECTION

3,<110> NEXGEN BIOTECHNOLOGIES, INC.
4, LEE, Sun
5, YOO, Jae-Geun
6, PARK, Sun-Hee
8,<120> METHOD FOR PREPARING FUSION POLYPEPTIDE COMPRISING
EPIDERMAL
9, GROWTH FACTOR AND HUMAN SERUM ALBUMIN IN PLANTS
11,<130> 20050-00004
13,<140> US 10/520,388
14,<141> 2005-01-03
16,<150> PCT/KR2003/01310
17,<151> 2003-07-02
19,<150> KR 2002-38165
20,<151> 2002-07-03
22,<160> 14
24,<170> PatentIn version 3.3

ERRORED LINES SECTION

STATISTICS SUMMARY

Application Serial Number: US 10/520,388
Alpha or Numeric or Xml: Numeric
Application Class:
Application File Date: 2005-01-03
Art Unit:
Software Application: PatentIN3.3
Total Number of Sequences: 14
Total Nucleotides: 530
Total Amino Acids: 53
Number of Errors: 0
Number of Warnings: 0
Number of Corrections: 0